ELOVL2 and neoplasm: Intriguingly, preliminary studies have suggested that ELOVL2 deficiency may function as a tumor suppressor in certain contexts, particularly in attenuating tamoxifen resistance through distinct molecular mechanisms (Kim et al., 2023).